S1 Ep8: Part 2 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with David Gandara MD
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
8m Aug 17, 2022
8m
S1 Ep8: Part 3 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Charu Aggarwal MD, MPH
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
6m Aug 17, 2022
6m
S1 Ep8: Part 4 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Julia Rotow MD
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
17m Aug 17, 2022
17m
S1 Ep7: Part 5 of 5: Top 10 Oncogenic Markers in NSCLC for 2022: An interview with Balazs Halmos MD, MS
Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available o...
10m Aug 17, 2022
10m
S1 Ep6: Tumor Board: Bridging Current Practices and New Therapeutic Developments in ER-Positive Breast Cancer
During this educational Tumor Board, breast cancer specialists will showcase challenging scenarios in metastatic and non-metastatic HR+ disease and contextualize data from pivotal clinical trials to optimize decision-making for patients with HR+/HER2- breast cancer. Featuring:  Fátima Cardoso, MD Director, Breast Unit Champalimaud Clinical Center Lisbon, Portugal   Mario Campone, MD, PhD ...
49m Jul 06, 2022
49m
S1 Ep5: Managing Your Patients with CKD
After you listen to this podcast, go to https://www.gotoper.com/2022consckd to learn more and get CME credit!
45m Apr 19, 2022
45m
S1 Ep4: What You Need to Know About the Evolving Role of TIL Therapy in Cancer Treatment
Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs ...
23m Apr 04, 2022
23m